EBITDA zoomed to ₹600.3 crore in the third quarter over a loss of ₹208.7 crore in the year-ago quarter. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,321.35, down by ₹88.55, or 6.28%, on the BSE.
EBITDA zoomed to ₹600.3 crore in the third quarter over a loss of ₹208.7 crore in the year-ago quarter. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,321.35, down by ₹88.55, or 6.28%, on the BSE.